“We have appreciated the opportunity to work constructively with the FDA on the review and finalization of our CRC protocol,” said Dr. Jacob Lalezari CEO. “With the agency’s input and our partnership with Syneos Health, we are well positioned to advance our clinical evaluation of leronlimab for oncology and make real strides towards developing the treatment paths of tomorrow.”

Dr. J once again emphasizes the improved relationship between Cytodyn and the FDA. This is for the benefit of current and future investors, individual and corporate. He seems to indicate that this relationship is on an equal par with the clinical progress. It is apparent because no such acknowledgement was made by previous management until it was too late. Welcome to the new and improved Cytodyn.